Bio-techne is a Top S&P 500 Stock. Germany's Merck is Paying a 24% Premium for the Company.

Dow Jones
Jun 26

Shares of Bio-Techne surged Thursday after Germany's Merck KGaA announced it agreed to purchase the company for $11.3 billion.

Bio-Techne stock jumped 20% to $70.55 on Thursday, placing it near the top of the S&P 500 for the trading session and set to log its best daily percentage gain since May 1, 2003, according to Dow Jones Market Data.

Merck KGaA plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock's closing price from Wednesday. The deal is expected to close later this year or early in 2027.

Merck said the acquisition of Bio-Techne will strengthen its presence in the life sciences market. Bio-Techne provides analytical technologies and life science tools used by researchers and drug manufacturers.

"Building on our strong track record in the life science business, this transaction strengthens our presence in some of the most exciting and fastest-growing areas of the life sciences," said Jean-Charles Wirth, a member of the executive board of Merck KGaA, in the media release.

Write to Kit Norton at kit.norton@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

June 25, 2026 15:12 ET (19:12 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10